Dr. Siddiqi on Rationale for the TRANSCEND CLL 004 Trial in CLL|SLL

Tanya Siddiqi, MD, discusses the rationale for the phase I/II TRANSCEND CLL 004 trial investigating the use of the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Website:
Twitter:
Facebook:
LinkedIn:

cancer,oncology,